Cynosure Group LLC Raises Stock Holdings in HCA Healthcare, Inc. (NYSE:HCA)

Cynosure Group LLC boosted its position in HCA Healthcare, Inc. (NYSE:HCA) by 20.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,359 shares of the company’s stock after buying an additional 233 shares during the period. Cynosure Group LLC’s holdings in HCA Healthcare were worth $552,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of HCA. MFA Wealth Advisors LLC purchased a new position in HCA Healthcare during the second quarter valued at approximately $27,000. Unique Wealth Strategies LLC acquired a new position in shares of HCA Healthcare in the 2nd quarter valued at $28,000. Bangor Savings Bank grew its position in HCA Healthcare by 112.5% during the second quarter. Bangor Savings Bank now owns 85 shares of the company’s stock valued at $27,000 after buying an additional 45 shares during the period. GPS Wealth Strategies Group LLC boosted its stake in shares of HCA Healthcare by 284.0% during the 2nd quarter. GPS Wealth Strategies Group LLC now owns 96 shares of the company’s stock worth $31,000 after acquiring an additional 71 shares in the last quarter. Finally, Capital Performance Advisors LLP purchased a new position in shares of HCA Healthcare in the 3rd quarter valued at about $41,000. 62.73% of the stock is currently owned by institutional investors and hedge funds.

HCA Healthcare Stock Down 1.1 %

Shares of NYSE HCA opened at $325.35 on Thursday. HCA Healthcare, Inc. has a 12-month low of $245.84 and a 12-month high of $417.14. The stock has a market cap of $82.41 billion, a P/E ratio of 14.61, a PEG ratio of 1.25 and a beta of 1.68. The company has a current ratio of 1.12, a quick ratio of 1.00 and a debt-to-equity ratio of 48.71. The business’s fifty day simple moving average is $374.98 and its 200-day simple moving average is $358.51.

HCA Healthcare Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 27th. Stockholders of record on Friday, December 13th will be given a dividend of $0.66 per share. This represents a $2.64 dividend on an annualized basis and a dividend yield of 0.81%. The ex-dividend date is Friday, December 13th. HCA Healthcare’s dividend payout ratio is presently 11.85%.

Insider Buying and Selling

In other HCA Healthcare news, insider Erol R. Akdamar sold 2,900 shares of the stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $353.00, for a total value of $1,023,700.00. Following the transaction, the insider now directly owns 6,843 shares in the company, valued at $2,415,579. This represents a 29.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Michael S. Cuffe sold 8,358 shares of the company’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $385.42, for a total transaction of $3,221,340.36. Following the completion of the transaction, the executive vice president now owns 29,678 shares of the company’s stock, valued at approximately $11,438,494.76. The trade was a 21.97 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 15,155 shares of company stock worth $5,608,990 over the last 90 days. 1.70% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research firms have recently commented on HCA. TD Cowen cut their price objective on HCA Healthcare from $450.00 to $440.00 and set a “buy” rating for the company in a research report on Monday, October 28th. Barclays dropped their target price on shares of HCA Healthcare from $396.00 to $392.00 and set an “overweight” rating on the stock in a research report on Friday, November 8th. Morgan Stanley assumed coverage on shares of HCA Healthcare in a research note on Tuesday, September 3rd. They issued an “equal weight” rating and a $427.00 price target on the stock. Truist Financial raised their target price on HCA Healthcare from $390.00 to $430.00 and gave the company a “buy” rating in a research report on Monday, August 19th. Finally, Raymond James downgraded shares of HCA Healthcare from an “outperform” rating to a “market perform” rating in a report on Friday, November 22nd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, HCA Healthcare presently has an average rating of “Moderate Buy” and a consensus price target of $380.29.

HCA Healthcare Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.